Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...
Optimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s Ataxia
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
MyChesCo on MSN4d
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia
Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) ...
Opinion
The Province4dOpinion
Franke James: Reframing my life after a rare degenerative disease diagnosis
Ataxia is a rare, degenerative neurological disease. It can affect a person’s ability to walk, talk and use fine motor skills. It comes in a literally dizzying array of types, stages and severity.
Promising Developments and Safety Confidence Boost Larimar Therapeutics’ Outlook
In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Larimar Therapeutics (LRMR – Research Report), ...
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will be eligible to screen in ...
Pharmabiz5d
Solid Biosciences’ AAV-based gene therapy candidate, SGT-212 for Friedreich’s ataxia receives US FDA fast track designation
Charlestown, Massachusetts Thursday, January 23, 2025, 15:00 Hrs [IST] ...
Keeping Positive
"My motto is to keep a positive outlook." Alan has ataxia, a degenerative disease which affects balance and co-ordination, but he's keeping active and won't let it ruin his life. "I call the ...